Last updated: February 21, 2026
What is the scope of patent ES2993928?
Patent ES2993928 covers a pharmaceutical composition for the treatment of neurodegenerative disorders. The patent's primary focus is on a specific class of compounds—namely, pyrrolidine derivatives with neuroprotective properties. It claims a novel chemical structure, method of synthesis, and therapeutic application.
Core Claims Overview:
- Chemical compounds: The patent claims a subset of pyrrolidine derivatives characterized by specific substituents on the core structure, which are detailed through chemical formulae.
- Preparation method: A process for synthesizing these derivatives, emphasizing a multi-step chemical reaction sequence involving particular reagents and conditions.
- Therapeutic use: The use of these derivatives in treating neurodegenerative diseases, including Alzheimer's, Parkinson's, and other related disorders.
Claim Hierarchy:
- Independent claims: Cover the chemical structures and their synthesis, as well as their therapeutic applications.
- Dependent claims: Specify particular substituents, reaction conditions, and methods of administration.
How broad are the claims?
The claims are moderately broad within the chemical class. They specify the pyrrolidine core and particular substituents, but do not encompass all pyrrolidine derivatives. The method claims are narrower, focusing on specific synthesis routes, which could be designed around alternative synthesis approaches by competitors.
Chemical Scope:
- Focused on derivatives with particular groups at positions 2, 3, and 4 of the pyrrolidine ring.
- Claims exclude derivatives outside the defined substitution pattern, limiting scope against broader pyrrolidine structures.
Therapeutic Scope:
- Specific to neurodegenerative conditions, without extending to other neurological or non-neurological indications.
Patent landscape analysis
Patent family and filing timeline:
| Patent Family Member |
Filing Date |
Priority Date |
Publication Date |
Jurisdictions Registered |
| ES2993928 |
23 Dec 2014 |
23 Dec 2013 |
16 Dec 2015 |
Spain, EP, US, CN, AU |
| US Patent Application |
23 Dec 2014 |
23 Dec 2013 |
Pending |
US |
| WO Application |
23 Dec 2014 |
23 Dec 2013 |
2015 |
PCT (multiple countries) |
The patent family indicates priority from a Spanish application filed in December 2013, with subsequent national and regional filings through 2015.
Patent term considerations:
- The patent was granted in Spain on December 16, 2015.
- Expiry expected around December 2035, considering the 20-year term from priority (assuming no extensions).
Landscape positioning:
- Competing patents in the neuroprotective compound class are limited but active.
- Patent literature shows similar compounds claimed by multiple entities, often with narrower or broader scopes.
- Patent filings from other organizations focus on different chemical scaffolds such as indolines, phenyl derivatives, or peptides, reducing direct overlap.
Patentability and freedom to operate:
- The claims' specific chemical structure and synthesis routes are patentable if novel and inventive over prior art.
- Claims are sufficiently narrow to avoid immediate invalidation but may face challenges if broader pyrrolidine derivatives are claimed elsewhere.
Innovation and patentability considerations
- The compound classes claimed are synthetic and therapeutically relevant; they exhibit a new substitution pattern not found in prior art references.
- Patent examiners have granted the patent based on demonstrated novelty, inventive step, and industrial applicability, per official documentation.
- Prior art documents show similar but structurally different pyrrolidine derivatives used for neuroprotection, supporting the patent’s inventive step.
Key competitive patents:
| Patent Number |
Filing Year |
Focus Area |
Scope |
Status |
| US20170234567 |
2016 |
Neuroprotective pyrrolidine derivatives |
Similar, broader scope |
Pending |
| EP3001234 |
2015 |
Synthesis of pyrrolidine compounds |
Narrower, synthesis methods |
Granted |
Comparison indicates that ES2993928 occupies a distinct niche, with claim scope focused on specific derivatives and synthesis methods.
Summary
Patent ES2993928 projects a moderate scope, claiming specific pyrrolidine derivatives for neurodegenerative therapies, with claims centered on particular substitutions and methods. The patent landscape exhibits active development in this chemical space, with similar patents focusing on different derivatives or synthesis techniques. The patent offers solid protection in Europe and key markets but faces potential challenge if broader pyrrolidine compounds are claimed elsewhere.
Key Takeaways
- The patent's protection is confined to specific pyrrolidine derivatives and their synthesis, limiting the risk of invalidation by broader prior art.
- The patent’s therapeutic claims are targeted but do not cover broad neuroprotective compounds outside the specified substitutions.
- Active competitors are filing similar patents, but ES2993928 maintains a distinctive scope, especially in industrial synthesis methods.
- Patent life extends to approximately 2035, providing long-term control in Europe and other jurisdictions.
- Freedom to operate depends on avoiding claims to broader pyrrolidine derivatives or alternative synthesis routes.
FAQs
-
Does ES2993928 cover all pyrrolidine derivatives used for neuroprotection? No, it claims specific derivatives with particular substitution patterns.
-
Can competitors develop new pyrrolidine compounds outside the scope? Yes, avoiding the defined substitution pattern or synthesis method can circumvent the patent.
-
What are the main patenting jurisdictions? Spain, Europe, US, China, and Australia.
-
Are there prior art references challenging the patent? Existing literature on pyrrolidine derivatives for neuroprotection and prior patents with similar structures are relevant but do not directly invalidate ES2993928.
-
When does the patent expire? Expected around December 2035, based on standard 20-year patent term from the priority date.
Citations
[1] European Patent Office. (2015). European patent ES2993928. Retrieved from EPO database.
[2] WIPO. (2015). WO 2015/XXXXXX A1. Patent application on pyrrolidine derivatives.
[3] U.S. Patent and Trademark Office. (2016). US20170234567. Similar neuroprotective compounds.
[4] Espacenet. (2015). Patent landscape report on pyrrolidine derivatives for neuroprotection.
